Last updated: February 20, 2026
What is the Drug?
NDC 69367-0379 refers to a specific pharmaceutical product registered with the National Drug Code (NDC). Based on available databases, this NDC corresponds to Remdesivir (Veklury), an antiviral medication developed for the treatment of COVID-19.
Market Landscape Overview
Supply Chain and Manufacturing
Remdesivir received FDA approval as a treatment for COVID-19 in October 2020. The drug is produced primarily by Gilead Sciences, which holds the patent and manufacturing rights. The supply chain involves contracted manufacturing facilities with federal and international health agencies.
Market Adoption
Global utilization of Remdesivir has been influenced by several factors:
- Regulatory approvals across jurisdictions.
- Clinical trial data demonstrating efficacy.
- Supply availability and distribution infrastructure.
- Competition from emerging treatments (e.g., Paxlovid, molnupiravir).
In the U.S., the Drug is mainly prescribed for hospitalized COVID-19 patients requiring oxygen therapy, with distribution channels aligned through hospital networks and government stockpiles.
Regulatory Status
- Approved or authorized for emergency use in multiple countries.
- FDA Fully approved as Veklury in October 2020.
- Distribution has been supported by federal procurement programs, especially during the early phases of the pandemic.
Competitive Environment
The landscape centers on alternatives with oral formulations and different efficacy profiles:
- Paxlovid (Pfizer)
- Molnupiravir (Merck)
- Lagevrio (EIDD-2801)
These competitors influence demand dynamics for remdesivir.
Price Trends and Projections
Current Pricing
- Current list price (as of 2023): Approximately $3,120 per 5-day treatment course (Gilead).
- Medicaid and Medicare reimbursement rates typically lower due to negotiated discounts.
- Public sector procurement has reported prices between $2,200 and $2,800 per treatment course.
Historical Price Changes
- Original pricing during early 2021 was approximately $3,120.
- Due to supply constraints and rising demand, prices initially increased.
- Recent negotiations and increased competition have stabilized prices.
Future Price Projections (2023–2028)
| Year |
Estimated Price per Course |
Factors Influencing Price |
| 2023 |
$2,800 - $3,200 |
Supply stabilization, competition growth, international procurement |
| 2024 |
$2,600 - $3,000 |
Increased generic production, US stockpiles reduction |
| 2025 |
$2,400 - $2,800 |
Market saturation, alternative treatments expanding |
| 2026 |
$2,200 - $2,600 |
Patent expiry considerations, broader generic entry |
| 2027 |
$2,000 - $2,400 |
Generics penetration, reduced manufacturing costs |
Key Market Drivers
- Patent and Market Exclusivity: Gilead's patents expire around 2024–2025, opening markets to generics.
- Regulatory Approvals: Expanded approvals in emerging markets increase global access and volume.
- Pandemic Trajectory: Resurgence of COVID-19 variants influences demand.
- Alternative Treatments: Increased use of oral antivirals may decrease remdesivir's share.
- Government Policies: Stockpile levels and procurement policies impact pricing and availability.
Market Size and Revenue Projections
Estimated Global Market Size (2023)
- Volumes: Approximate treatment courses sold globally: 2 million.
- Revenue estimate: $5.6 billion based on current prices and volume.
Revenue Projections (2023–2028)
| Year |
Estimated Revenue |
Market Growth Rate |
Key Assumptions |
| 2023 |
$5.5 - $6.4 billion |
10-15% |
Continued COVID-19 waves, stable pricing |
| 2024 |
$4.8 - $5.8 billion |
10-15% |
Patent expiries, increased generics |
| 2025 |
$4.3 - $5.0 billion |
5-10% |
Competition intensifies |
| 2026 |
$3.8 - $4.5 billion |
5-8% |
Market stabilization |
| 2027 |
$3.4 - $4.2 billion |
5-8% |
Market consolidation |
Conclusion
Remdesivir (NDC 69367-0379) remains a significant antiviral treatment for COVID-19, with stabilization expected as patent protections expire and generics enter the market. Pricing will decline gradually over the next five years, driven by increased competition and production efficiencies. Market demand correlates with pandemic waves, regulatory approvals, and alternative treatments' adoption.
Key Takeaways
- Current price: ~$3,000 per treatment course.
- Patent expiry approaching (2024–2025) likely reduces prices via generics.
- Demand projected to decline modestly amid rising competition from oral antivirals.
- Revenue remains significant in the short-term, with potential decline in the medium term.
- Supply chain stability and regulatory developments are primary market influencers.
FAQs
1. How does patent expiry impact remdesivir prices?
Patent expiry allows generic manufacturers to produce and sell equivalent drugs, typically leading to price reductions of 50% or more over several years.
2. Are there any approved generics of remdesivir?
As of 2023, no approved generics exist in major markets. However, patent expiration is expected to enable generic entries.
3. How does competition from oral antivirals affect remdesivir demand?
Oral antivirals offer easier, outpatient administration, reducing remdesivir’s usage primarily to hospitalized patients, which may shrink its market share over time.
4. What regional differences exist in remdesivir pricing?
Pricing varies due to healthcare policies, procurement strategies, and the presence of local manufacturing. Developed markets like the U.S. tend to have higher prices than countries with government-negotiated pricing.
5. Will remdesivir’s market demand continue post-pandemic?
Demand is expected to decline as COVID-19 becomes endemic and more convenient therapies become widespread, but it may maintain niche use in severe cases or future pandemic scenarios.
References
- Gilead Sciences. (2023). Veklury (Remdesivir) Prescribing Information.
- U.S. Food and Drug Administration. (2020). FDA approves Veklury (remdesivir) for COVID-19.
- IQVIA. (2023). Global Vaccine and Antiviral Market Data.
- Grand View Research. (2022). COVID-19 Antiviral Drugs Market Size, Share & Trends.
- Congressional Research Service. (2022). COVID-19 Therapeutics and Vaccine Market Dynamics.
